Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 418.20B |
| Revenue (ttm) | 78.81B |
| Net Income (ttm) | 21.48B |
| Shares Out | n/a |
| EPS (ttm) | 8.85 |
| PE Ratio | 19.47 |
| Forward PE | 18.00 |
| Dividend | 4.57 (2.64%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 2,572 |
| Average Volume | 3,933 |
| Open | 173.24 |
| Previous Close | 173.90 |
| Day's Range | 172.38 - 174.64 |
| 52-Week Range | 128.16 - 179.72 |
| Beta | 0.36 |
| RSI | 56.19 |
| Earnings Date | Jan 21, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
JNJ releases new data bolstering Inlexzo for bladder cancer
Johnson & Johnson's (JNJ) SunRISe-1 Study Shows Promising Results for Bladder Cancer Treatment
Johnson & Johnson's (JNJ) SunRISe-1 Study Shows Promising Results for Bladder Cancer Treatment
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this t...
Guggenheim Raises Price Target for JNJ to $227, Maintains 'Buy' Rating | JNJ Stock News
Guggenheim Raises Price Target for JNJ to $227, Maintains 'Buy' Rating | JNJ Stock News
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Johnson & Johnson (JNJ) settling at $202.48, representing a -1.39% change from its previous close.
Johnson & Johnson at Citi Global Healthcare Conference Transcript
Johnson & Johnson at Citi Global Healthcare Conference Transcript
Johnson & Johnson Named Top Dividend Stock With Insider Buying and 2.53% Yield (JNJ)
In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. ...
JNJ January 2026 Options Begin Trading
Investors in Johnson & Johnson (Symbol: JNJ) saw new options begin trading today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the JNJ optio...
Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Only Six Dow Components With Recent Insider Buying, JNJ is One of Them
The officers and directors of a company tend to have a unique inside view into the business, so when these insiders make purchases, investors are wise to take notice. Presumably the only reason for a ...
3 Dividend Stocks Wall Street is Piling Into Before 2026
There is an apparent shift in how Wall Street views the stock market, as retail investors are increasingly doubting the AI rally. This is causing investors to pile into dividend stocks like Johnson & ...
Janux Therapeutics Stock Hits 52-Week Low After Trial Update
Janux Therapeutics Inc. (NASDAQ: JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate ...
Notable ETF Inflow Detected - XLV, JNJ, ABBV, MRK
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
Snatch This Bargain Even Cheaper Than Director Morikis Did
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 26, Johnson & Johnson's Director, John G. Morik...
Barclays Raises Price Target for Johnson & Johnson (JNJ) to $197 | JNJ Stock News
Barclays Raises Price Target for Johnson & Johnson (JNJ) to $197 | JNJ Stock News
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC Capital Markets upgraded Neumora Therapeutics, Inc. (NASDAQ: NMRA) from Sector Perform to Outperform , with an increased price forecast from $4 to $7. The company is evolving beyond neurology and...
American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. We initiated a position in this cust...
16 Quality Stocks to Own for a Volatile Market
The S&P 500 has staged an impressive rebound, but is in for more swings.
Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-t...
2 Top Dividend Stocks to Buy and Hold
Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.